Skip to main content
SpringerLink
Log in

Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-β1a?

  • Practice Point
  • Published:

From Nature Clinical Practice Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Panitch H et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59: 1496–1506

    Article  CAS  Google Scholar 

  2. Rask C et al. (online 7 March 2002) Comparative study of Rebif to Avonex and orphan exclusivity. [http://www.fda.gov/cder/biologics/review/ifnbser030702r1.pdf] (accessed 6 July 2005)

    Google Scholar 

  3. de la Fuente-Fernández R et al. (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293: 1164–1166

    Article  Google Scholar 

  4. Wager TD et al. (2004) Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303: 1162–1167

    Article  CAS  Google Scholar 

  5. Francis GS et al. (2005) Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65: 48–55

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Emma Campbell, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Mellen Center for Multiple Sclerosis Treatment and Research,

    Robert J Fox & Richard A Rudick

  2. Director of the Mellen Center for Multiple Sclerosis Treatment and Research,

    Robert J Fox & Richard A Rudick

  3. Chairman of the Division of Clinical Research at the Cleveland Clinic Foundation, Cleveland, OH, USA

    Robert J Fox & Richard A Rudick

Authors
  1. Robert J Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard A Rudick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J Fox.

Ethics declarations

Competing interests

Drs Fox and Rudick have received grant support or honoraria for speaking and consulting services in the past 3 years from Accorda Therapeutics, Biogen Idec, Centocor, Merck, Millenium, National Institutes Of Health, National Multiple Sclerosis Society, Questcor, Serono, Teva Neuroscience and Vertex Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, R., Rudick, R. Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-β1a?. Nat Rev Neurol 1, 16–17 (2005). https://doi.org/10.1038/ncpneuro0041

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0041

  • Springer Nature Limited

Search

Navigation